ArticleScientific reports2025
Exploratory study on the efficacy of Lingze mixture in gouty arthritis rats and preliminary analysis of its potential mechanisms via transcriptome sequencing.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Lingze mixture (LM), a traditional Chinese herbal formula, has demonstrated clinical efficacy in treating gouty arthritis (GA). However, its pharmacological mechanisms remain largely unexplored. This study aimed to conduct an exploratory investigation into the anti-inflammatory effects of LM in a GA rat model and to preliminarily identify potential signaling pathways involved through transcriptome analysis. A rat GA model was induced by monosodium urate (MSU) injection. Animals were treated with LM at low, medium, or high doses, with etoricoxib as a positive control. Synovial inflammation was assessed histologically (H&E staining). Protein expression of TLR4, MyD88, and NF-κB was detected by immunohistochemistry (IHC). To generate mechanistic hypotheses, RNA sequencing (RNA-seq) was performed on synovial tissues from the blank, model, and medium-dose LM groups. LM treatment significantly attenuated MSU-induced synovitis and dose-dependently reduced the protein levels of TLR4, MyD88, and NF-κB. Transcriptome analysis revealed significant enrichment of the TLR4/MyD88/NF-κB and MAPK signaling pathways in the model group. Notably, medium-dose LM treatment appeared to modulate these pathways, along with alanine, aspartate, and glutamate metabolism. Our findings confirm the anti-gout efficacy of LM in vivo and provide preliminary evidence suggesting its action may be associated with the modulation of the TLR4/MyD88/NF-κB pathway. This study offers valuable mechanistic clues and a foundation for further in-depth investigation into LM's mode of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.